3/7
09:14 pm
asnd
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China [Yahoo! Finance]
Low
Report
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China [Yahoo! Finance]
3/7
09:00 pm
asnd
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China
Low
Report
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China
3/4
08:30 am
asnd
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
Medium
Report
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
2/15
02:01 pm
asnd
Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy? [Yahoo! Finance]
Low
Report
Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy? [Yahoo! Finance]
2/15
11:00 am
asnd
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? [Yahoo! Finance]
Low
Report
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? [Yahoo! Finance]
2/10
07:25 am
asnd
US$172 - That's What Analysts Think Ascendis Pharma A/S (NASDAQ:ASND) Is Worth After These Results [Yahoo! Finance]
Low
Report
US$172 - That's What Analysts Think Ascendis Pharma A/S (NASDAQ:ASND) Is Worth After These Results [Yahoo! Finance]
2/8
11:43 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Citigroup Inc. from $146.00 to $182.00. They now have a "buy" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Citigroup Inc. from $146.00 to $182.00. They now have a "buy" rating on the stock.
2/8
10:18 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/8
08:32 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Wedbush from $207.00 to $225.00. They now have an "outperform" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Wedbush from $207.00 to $225.00. They now have an "outperform" rating on the stock.
2/7
04:16 pm
asnd
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results [Yahoo! Finance]
Low
Report
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results [Yahoo! Finance]
2/7
04:01 pm
asnd
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
Low
Report
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
2/7
09:50 am
asnd
3 Top-Ranked Small-Cap Growth Mutual Funds Worth Betting On [Yahoo! Finance]
Low
Report
3 Top-Ranked Small-Cap Growth Mutual Funds Worth Betting On [Yahoo! Finance]
2/7
08:30 am
asnd
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Low
Report
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/6
10:37 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Cantor Fitzgerald from $152.00 to $173.00. They now have an "overweight" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Cantor Fitzgerald from $152.00 to $173.00. They now have an "overweight" rating on the stock.
2/5
01:13 pm
asnd
Hypoparathyroidism Market is Expected to Exhibit Impressive Growth by 2032, Assesses DelveInsight | Leading Companies Developing Therapies - Ascendis Pharma, Amolyt Pharma, Bridgebio, Calcilytix Therapeutics [Yahoo! Finance]
Low
Report
Hypoparathyroidism Market is Expected to Exhibit Impressive Growth by 2032, Assesses DelveInsight | Leading Companies Developing Therapies - Ascendis Pharma, Amolyt Pharma, Bridgebio, Calcilytix Therapeutics [Yahoo! Finance]
1/31
04:34 pm
asnd
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024 [Yahoo! Finance]
Medium
Report
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024 [Yahoo! Finance]
1/31
04:15 pm
asnd
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
Medium
Report
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
1/31
04:05 pm
asnd
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism [Yahoo! Finance]
Medium
Report
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism [Yahoo! Finance]
1/31
04:01 pm
asnd
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
Medium
Report
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
1/29
08:49 am
asnd
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors [Yahoo! Finance]
Low
Report
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors [Yahoo! Finance]
1/29
08:30 am
asnd
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
Low
Report
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
1/15
06:45 am
asnd
Chronic Disease Markets for Sustained Released Injectables: The Trend toward Self-Administration
Low
Report
Chronic Disease Markets for Sustained Released Injectables: The Trend toward Self-Administration
1/11
06:55 am
asnd
Recycled Carbon Fiber Market To Reach USD 519.7 Million By 2032 Report By DataHorizzon Research [Yahoo! Finance]
Low
Report
Recycled Carbon Fiber Market To Reach USD 519.7 Million By 2032 Report By DataHorizzon Research [Yahoo! Finance]
1/10
08:37 am
asnd
Investors ignore increasing losses at Ascendis Pharma (NASDAQ:ASND) as stock jumps 11% this past week [Yahoo! Finance]
Low
Report
Investors ignore increasing losses at Ascendis Pharma (NASDAQ:ASND) as stock jumps 11% this past week [Yahoo! Finance]
1/10
04:48 am
asnd
Chronic Disease Management Revolutionized by Sustained Release Injectables: New Research Unveiled [Yahoo! Finance]
Low
Report
Chronic Disease Management Revolutionized by Sustained Release Injectables: New Research Unveiled [Yahoo! Finance]